{"Clinical Trial ID": "NCT00448279", "Intervention": ["INTERVENTION 1:", "- Chemotherapy alone", "Participants received chemotherapy until disease progression, unacceptable toxicity or death; timing and dose at the discretion of the investigator and according to local prescribing guidelines and the centre's standard practice.", "INTERVENTION 2:", "- Chemotherapy + Trastuzumab", "Participants received trastuzumab at the rate of 2 mg/kg, IV, every 7 days, or 6 mg/kg, IV, every 3 weeks, at the discretion of the investigator. Participants also received chemotherapy; timing and dose at the discretion of the investigator and according to local prescribing guidelines and standard centre practice."], "Eligibility": ["Incorporation criteria:", "Women, >=18 years of age;", "Metastatic breast cancer;", "- HER2 overexpression (IHC 3+ and/or FISH positive);", "\u2022 Disease progression during or after chemotherapy 1st previous line plus Herceptin;", "It is planned to receive second-line chemotherapy.", "- Exclusion criteria:", "Incompatibility with previous treatment with Herceptin;", "A pregnancy."], "Results": ["Performance measures:", "* Progression-free survival rate (PFS) - Percentage of participants participating in an event", "The PFS was defined as the time of randomization up to the date of documented progression of the disease according to the criteria for assessing the response in version 1.1 of solid tumours (RECIST), or the date of onset of a second primary cancer, or the date of death of any cause, whichever occurs first.", "Time frame: Baseline (BL) and every 8 weeks thereafter", "Results 1:", "Title of the arm/group: Chemotherapy alone", "Description of the arm/group: Participants received chemotherapy until disease progression, unacceptable toxicity or death; timing and dose at the discretion of the investigator and according to local prescribing guidelines and standard centre practice.", "Total number of participants analysed: 29", "Type of measurement: Number", "Unit of measure: percentage of participants 58.6", "Results 2:", "Title of the arm/group: Chemotherapy + Trastuzumab", "Participants received trastuzumab at 2 mg/kg, IV, every 7 days, or 6 mg/kg, IV, every 3 weeks, at the discretion of the investigator. Participants also received chemotherapy; timing and dose at the discretion of the investigator and according to local prescribing guidelines and standard centre practice.", "Total number of participants analysed: 29", "Type of measurement: Number", "Unit of measure: percentage of participants 58.6"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/26 (15.38 per cent)", "Febrile neutropenia * 1/26 (3.85 %)", "Gastrointestinal volvule * 20/26 (0.00 %)", "General Malaise * 21/26 (3.85%)", "Hospitalization for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%)", "Acute renal impairment * 21/26 (3.85%)", "Adverse Events 2:", "Total: 1/28 (3.57 per cent)", "Febrile neutropenia * 0/28 (0.00 %)", "Gastrointestinal volvulus * 21/28 (3.57 per cent)", "General Malaise * 20/28 (0.00%)", "Hospitalization for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00 %)", "Acute renal impairment * 20/28 (0.00 %)"]}